Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma.

Yang MH, Yen CH, Chen YF, Fang CC, Li CH, Lee KJ, Lin YH, Weng CH, Liu TT, Huang SF, Teh BT, Chen YA.

Sci Rep. 2019 Feb 22;9(1):2552. doi: 10.1038/s41598-018-36810-5.

2.

Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma.

Li CH, Yen CH, Chen YF, Lee KJ, Fang CC, Zhang X, Lai CC, Huang SF, Lin HK, Arthur Chen YM.

Int J Cancer. 2017 May 15;140(10):2284-2297. doi: 10.1002/ijc.30652.

3.
4.

The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.

Lan X, Xiao F, Ding Q, Liu J, Liu J, Li J, Zhang J, Tian DA.

J Mol Histol. 2014 Dec;45(6):689-96. doi: 10.1007/s10735-014-9593-0. Epub 2014 Aug 24.

PMID:
25151370
5.

Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.

Lissanu Deribe Y, Shi Y, Rai K, Nezi L, Amin SB, Wu CC, Akdemir KC, Mahdavi M, Peng Q, Chang QE, Hornigold K, Arold ST, Welch HC, Garraway LA, Chin L.

Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1296-305. doi: 10.1073/pnas.1513801113. Epub 2016 Feb 16.

6.

Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations.

Horrigan SK, Courville P, Sampey D, Zhou F, Cai S; Reproducibility Project: Cancer Biology.

Elife. 2017 Jan 19;6. pii: e21634. doi: 10.7554/eLife.21634.

7.

PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.

Yang J, Gong X, Ouyang L, He W, Xiao R, Tan L.

Oncol Lett. 2016 Aug;12(2):1139-1143. Epub 2016 Jun 8.

8.

Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma.

Lissanu Deribe Y.

Small GTPases. 2016 Jul 2;7(3):178-85. doi: 10.1080/21541248.2016.1178366. Epub 2016 Apr 25.

9.

Melanoma genome sequencing reveals frequent PREX2 mutations.

Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA.

Nature. 2012 May 9;485(7399):502-6. doi: 10.1038/nature11071.

10.

p21-activated Kinases (PAKs) Mediate the Phosphorylation of PREX2 Protein to Initiate Feedback Inhibition of Rac1 GTPase.

Barrows D, Schoenfeld SM, Hodakoski C, Silkov A, Honig B, Couvillon A, Shymanets A, N├╝rnberg B, Asara JM, Parsons R.

J Biol Chem. 2015 Nov 27;290(48):28915-31. doi: 10.1074/jbc.M115.668244. Epub 2015 Oct 5.

11.

Molecular mechanism of hepatocarcinogenesis.

Sheu JC.

J Gastroenterol Hepatol. 1997 Oct;12(9-10):S309-13. Review.

PMID:
9407351
12.

Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.

Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J.

Gut. 2015 May;64(5):820-9. doi: 10.1136/gutjnl-2013-306228. Epub 2014 Jun 9.

13.

HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.

Momosaki S, Nakashima Y, Kojiro M, Tabor E.

J Viral Hepat. 2005 May;12(3):325-9.

PMID:
15850475
14.

PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.

Mense SM, Barrows D, Hodakoski C, Steinbach N, Schoenfeld D, Su W, Hopkins BD, Su T, Fine B, Hibshoosh H, Parsons R.

Sci Signal. 2015 Mar 31;8(370):ra32. doi: 10.1126/scisignal.2005840.

15.

Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.

Zhang W, He H, Zang M, Wu Q, Zhao H, Lu LL, Ma P, Zheng H, Wang N, Zhang Y, He S, Chen X, Wu Z, Wang X, Cai J, Liu Z, Sun Z, Zeng YX, Qu C, Jiao Y.

Gastroenterology. 2017 Jul;153(1):249-262.e2. doi: 10.1053/j.gastro.2017.03.024. Epub 2017 Mar 29.

PMID:
28363643
16.

Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma.

Shen J, Tsoi H, Liang Q, Chu ES, Liu D, Yu AC, Chan TF, Li X, Sung JJ, Wong VW, Yu J.

Oncogene. 2016 Dec 8;35(49):6271-6280. doi: 10.1038/onc.2016.162. Epub 2016 May 2.

17.

Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.

Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM.

Genomics. 2013 Aug;102(2):74-83. doi: 10.1016/j.ygeno.2013.04.001. Epub 2013 Apr 11. Review.

18.
19.

Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma.

Huang SF, Chen YT, Lee WC, Chang IC, Chiu YT, Chang Y, Tu HC, Yuh CH, Matsuura I, Shih LY, Lai MW, Wu HD, Chen MF, Yeh CT.

PLoS One. 2014 Feb 24;9(2):e89753. doi: 10.1371/journal.pone.0089753. eCollection 2014.

20.

Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation.

Zhou Y, Zhao Y, Gao Y, Hu W, Qu Y, Lou N, Zhu Y, Zhang X, Yang H.

J Exp Clin Cancer Res. 2017 Mar 10;36(1):42. doi: 10.1186/s13046-017-0510-8.

Supplemental Content

Support Center